NYSE:PFEPfizer Stock Price, Forecast & News

Pfizer's stock was trading at $32.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PFE stock has increased by 7.5% and is now trading at $34.57. View which stocks have been mosted impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Pfizer.

Pfizer is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Pfizer.

Pfizer will be holding an earnings conference call on Tuesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Pfizer Inc. (NYSE:PFE) announced its earnings results on Tuesday, January, 28th. The biopharmaceutical company reported $0.55 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by $0.02. The biopharmaceutical company earned $12.69 billion during the quarter, compared to the consensus estimate of $12.73 billion. Pfizer had a return on equity of 27.01% and a net margin of 31.44%. Pfizer's revenue for the quarter was down 9.2% on a year-over-year basis. During the same period last year, the firm earned $0.64 EPS. View Pfizer's earnings history.

Pfizer announced a quarterly dividend on Monday, December 16th. Investors of record on Friday, January 31st will be paid a dividend of $0.38 per share on Friday, March 6th. This represents a $1.52 dividend on an annualized basis and a yield of 4.40%. The ex-dividend date is Thursday, January 30th. This is a boost from Pfizer's previous quarterly dividend of $0.36. View Pfizer's dividend history.

Pfizer announced that its board has approved a stock repurchase plan on Friday, December 14th 2018, which allows the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 3.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's leadership believes its stock is undervalued.

Pfizer issued an update on its FY20 earnings guidance on Tuesday, January, 28th. The company provided earnings per share guidance of $2.82-$2.92 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.72. The company issued revenue guidance of $48.5-$50.5 billion, compared to the consensus revenue estimate of $47.44 billion.

12 Wall Street analysts have issued 12 month target prices for Pfizer's stock. Their forecasts range from $36.00 to $53.00. On average, they expect Pfizer's stock price to reach $41.30 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View analysts' price targets for Pfizer.

Press coverage about PFE stock has trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pfizer earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutPfizer.

Pfizer saw a increase in short interest in March. As of March 13th, there was short interest totaling 59,077,400 shares, an increase of 10.1% from the February 27th total of 53,670,000 shares. Based on an average daily volume of 25,250,000 shares, the short-interest ratio is currently 2.3 days. Currently, 1.1% of the shares of the stock are sold short. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), General Electric (GE), Bank of America (BAC), AbbVie (ABBV), Walt Disney (DIS) and Exxon Mobil (XOM).

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer's stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.02%), Nexus Investment Management Inc. (0.01%), Park National Corp OH (0.01%), Private Asset Management Inc. (0.01%), Callahan Advisors LLC (0.01%) and Cullinan Associates Inc. (0.00%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View institutional ownership trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including M&R Capital Management Inc., Neville Rodie & Shaw Inc., Burns J W & Co. Inc. NY, Stillwater Investment Management LLC, Chemung Canal Trust Co., Salomon & Ludwin LLC, Fulcrum Equity Management, and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, and Frank A Damelio. View insider buying and selling activity for Pfizer.

PFE stock was acquired by a variety of institutional investors in the last quarter, including American National Bank, State of Alaska Department of Revenue, Nexus Investment Management Inc., Park National Corp OH, IMS Capital Management, CLARET ASSET MANAGEMENT Corp, Pensionfund Sabic, and First Financial Bank Trust Division. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc, and Scott Gottlieb. View insider buying and selling activity for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $34.57.

Pfizer has a market capitalization of $191.78 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis. Pfizer employs 88,300 workers across the globe. View additional information about Pfizer.

The official website for Pfizer is http://www.pfizer.com/.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.